Date:	2023/02/09	
Your Name:	Qi Shi	
Manuscript Title:_	A novel pyroptos	is-related model for prognostic prediction in esophageal squamous cell
carcinoma		
Manuscript numbe	er (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	Qi ShiNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	Qi ShiNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	Qi ShiNone	
4	Consulting fees	Qi ShiNone	

5	Payment or honoraria for	Qi ShiNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	Qi ShiNone	
	testimony		
7	Support for attending meetings and/or travel	Qi ShiNone	
	-		
8	Patents planned, issued or	Qi ShiNone	
	pending		
9	Participation on a Data	Qi ShiNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	Qi ShiNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Qi ShiNone	
12	Receipt of equipment,	Qi ShiNone	
	materials, drugs, medical		
	writing, gifts or other		
40	services	0:01: 11	
13	Other financial or non-	Qi ShiNone	
	financial interests		

Please summarize the above conflict of interest in the following box:

None			

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	2023/02/09	
Your Name:	Meichen Liu	
Manuscript Title:	A novel pyroptosis-related model for prognostic predi	iction in esophageal squamous cell
carcinoma		
Manuscript numbe	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Meichen LiuNone	
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	Meichen LiuNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	Meichen LiuNone	
4	Consulting fees	Meichen LiuNone	

5	Payment or honoraria for	Meichen LiuNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	Meichen LiuNone	
	testimony		
7	Company for attanding	Majahan Liu Nana	
/	Support for attending meetings and/or travel	Meichen LiuNone	
	meetings and/or traver		
8	Patents planned, issued or	Meichen Liu None	
0	pending	Welchen Liu_None	
	pending		
9	Participation on a Data	Meichen Liu None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	Meichen LiuNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Meichen LiuNone	
12	Descipt of anytings out	Meichen Liu None	
12	Receipt of equipment, materials, drugs, medical	Meichen LiuNone	
	writing, gifts or other		
	services		
13	Other financial or non-	Meichen Liu None	
	financial interests		
Plea	ise summarize the above co	nflict of interest in the foll	owing box:

None		

Please place an "X" next to the following statement to indicate your agreement:

 $_{\rm X}_$ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	2023/02/09	
Your Name:	Shuo Wang	
Manuscript Title:	A novel pyroptosis-related model for prognostic predic	tion in esophageal squamous cell
carcinoma		
Manuscript numbe	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shuo WangNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Shuo WangNone	
3	Royalties or licenses	Shuo WangNone	
4	Consulting fees	Shuo WangNone	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial interests Please summarize the above conflict of interest in the following box:						
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial interests						
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial interests	5	Payment or honoraria for	Shuo WangNone			
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial interests Shuo Wang_None						
educational events Payment for expert testimony Support for attending meetings and/or travel Begin Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Leadership or unpaid Shuo Wang_None						
Shuo Wang_None Shuo Wang_None						
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Thus Wang None Shuo Wang None						
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests	6	,	Shuo WangNone			
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests		testimony				
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests	_	C 15 11 11	CI M			
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Shuo Wang_None	7		Shuo WangNone			
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Shuo Wang_None						
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Shuo Wang_None						
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests	8	· · · · · · · · · · · · · · · · · · ·	Shuo WangNone			
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Shuo WangNone Shuo WangNone Shuo WangNone 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Shuo WangNone Shuo WangNone Shuo WangNone		pending				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Shuo WangNone Shuo WangNone Shuo WangNone 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Shuo WangNone Shuo WangNone Shuo WangNone						
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Shuo Wang_None Shuo Wang_NoneShuo Wang_NoneShuo Wang_NoneShuo Wang_None	9	· ·	Shuo WangNone			
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Shuo Wang_None Shuo Wang_None Shuo Wang_None Shuo Wang_None Shuo Wang_None Shuo Wang_None						
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Shuo Wang_None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Shuo Wang_None Shuo Wang_NoneShuo Wang_None		•				
committee or advocacy group, paid or unpaid 11 Stock or stock options Shuo Wang_None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Shuo Wang_None Shuo Wang_None Shuo Wang_None	10		Shuo WangNone			
group, paid or unpaid 11 Stock or stock options Shuo WangNone 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Shuo WangNone Shuo WangNone Shuo WangNone						
11 Stock or stock optionsShuo Wang_NoneShuo Wang_NoneS		,				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Shuo Wang_None Shuo Wang_None Shuo Wang_None	11		Shuo Wang None			
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Shuo Wang_None	11	Stock of Stock Options	JIIGO VVAIIBIVOITE			
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Shuo Wang_None						
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Shuo Wang_None	12	Receipt of equipment.	Shuo Wang None			
writing, gifts or other services 13 Other financial or non-financial interests Shuo Wang_None						
services 13 Other financial or non- financial interests Shuo Wang_None						
financial interests						
	13	Other financial or non-	Shuo WangNone			
Please summarize the above conflict of interest in the following box:		financial interests				
Please summarize the above conflict of interest in the following box:						
Please summarize the above conflict of interest in the following box:						
Please summarize the above conflict of interest in the following box:						
-	Plea	Please summarize the above conflict of interest in the following box:				

Please place an "X" next to the following statement to indicate your agreement:

 $_X_$ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	_2023/02/09	
Your Name:	Pengpeng Ding	
Manuscript Title:	_ A novel pyroptosis-related model for prognostic prediction in esophage	eal squamous cell
carcinoma		
Manuscript number	(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	Pengpeng DingNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	Pengpeng DingNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	Pengpeng DingNone	
4	Consulting fees	Pengpeng DingNone	

5	Payment or honoraria for	Pengpeng DingNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	Pengpeng DingNone	
	testimony		
7	Support for attending	Pengpeng DingNone	
	meetings and/or travel		
_			
8	Patents planned, issued or	Pengpeng DingNone	
	pending		
_	5 5 .	5. 1	
9	Participation on a Data	Pengpeng DingNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	Pengpeng Ding None	
10	in other board, society,	Pengpeng Ding_None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Pengpeng DingNone	
	•		
12	Receipt of equipment,	Pengpeng DingNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	Pengpeng DingNone	
	financial interests		
		(II (

Please summarize the above conflict of interest in the following box:

None		

Please place an "X" next to the following statement to indicate your agreement:

 $_X_$ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	2023/02/09	
Your Name:	Yuefu Wang	
Manuscript Title:	A novel pyroptosis	-related model for prognostic prediction in esophageal squamous cell
carcinoma		
Manuscript number	(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Yuefu WangNone	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	Yuefu WangNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	Yuefu WangNone	
4	Consulting fees	Yuefu WangNone	

5	Payment or honoraria for	Yuefu WangNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	Yuefu WangNone	
	testimony		
7	Support for attending	Yuefu WangNone	
	meetings and/or travel		
8	Patents planned, issued or	Yuefu WangNone	
	pending		
	F		
9	Participation on a Data	Yuefu WangNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	Yuefu Wang None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Yuefu WangNone	
12	Receipt of equipment,	Yuefu WangNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	Yuefu WangNone	
	financial interests		

Please summarize the above conflict of interest in the following box:

None		

Please place an "X" next to the following statement to indicate your agreement:

 $_{\rm X}_$ I certify that I have answered every question and have not altered the wording of any of the questions on this form.